Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$0.48
$0.01(2.07%)
At close: 4:00 PM EDT
$0.48
$0.01(2.07%)
Day’s Range― - ―
52-Week Range$0.36 - $4.00
Previous CloseN/A
Volume40.38K
Average Volume (3M)14.87M
Market Cap
$22.56M
Enterprise Value$30.86M
Total Cash (Recent Filing)$8.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 05, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding56,349,170
10 Day Avg. Volume848,985
30 Day Avg. Volume14,865,552
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.29K
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$3.50Price Target Upside629.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$275.00K
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt removes refinancing pressure and interest obligations while giving HeartBeam greater flexibility to fund product development. The higher equity base also provides a stronger foundation for commercialization, although operating performance still determines whether that capital can become self-sustaining.
Regulatory AdvancementFDA Breakthrough status and TAP acceptance strengthen the product’s regulatory pathway and may improve access to agency guidance. This does not guarantee approval, but it is a durable development that can support pivotal-trial planning, clinical adoption, and the company’s positioning in portable cardiac diagnostics.
Clinical And IP PlatformA protected signal-processing platform combined with rapid clinical enrollment supports differentiated product development and evidence generation. Multiple validated form factors and issued patents may help HeartBeam address post-discharge, ambulatory, and remote-monitoring use cases over the coming quarters.
Bears Say
No Revenue And Widening LossesThe absence of reported revenue means HeartBeam has not yet demonstrated a recurring commercial engine to support its operating base. Large and widening losses increase the distance to self-funded growth, making future progress dependent on converting development and clinical work into sustained customer revenue.
Persistent Cash BurnNegative operating and free cash flow show that the business continues to consume capital rather than generate it. Even with expected efficiency improvements, ongoing burn can constrain investment choices and require additional financing before commercialization produces enough receipts to fund operations.
Early Commercial AdoptionInitial deployments demonstrate some market entry but remain too limited to establish repeatable demand or meaningful scale. Dependence on integrating the device into clinical workflows could lengthen adoption cycles, delay revenue acceleration, and keep the company exposed to execution risk during commercialization.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.35 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $22.56M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Nov 05, 2026 which is in 7 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Aug 13, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.086 by -$0.014.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.09.
How many shares outstanding does HeartBeam have?
HeartBeam has 56,349,170 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.086. Following the earnings report the stock price went down -15.28%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HeartBeam
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
BEAT Company Deck
BEAT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress on clinical validation, strong IP protection, completed product development milestones, early commercial deployments, and improving cash efficiency — all meaningful positives. Key risks remain: commercial revenue is nascent, regulatory approval for the heart attack detection indication is pending (pre-submitted to FDA), cash balances require disciplined execution to reach profitability, and a leadership transition created near-term one-time costs. On balance, the highlights (clinical momentum, regulatory progress, IP strength, cost reductions and runway extension) outweigh the lowlights (early revenue, regulatory uncertainty, continued net losses), supporting a cautiously positive outlook.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$3.50
▲(629.17% Upside)
Technical Analysis
Ownership Overview
16.84% Insiders
2.57% Mutual Funds
0.87% Other Institutional Investors
75.74% Public Companies and
Individual Investors